



Media Release: Sydney, Australia. 7 March, 2023.

## Phebra Launches New Australian-Made Sterile Theatre Pack

Australian pharmaceutical group Phebra ('Company') is excited to launch its first product in a sterile theatre pack, manufactured on its new production line at the Company's expanded multi-purpose Sydney manufacturing plant.

**Bupivacaine 0.5% with Adrenaline 1:200,000 Phebra** is a combination of an anaesthetic and analgesic medication and is used mainly by surgeons and anaesthetists for field blocks and spinal blocks<sup>1</sup>. This Australian-made sterile theatre pack product is available to public and private hospitals across the country.

Phebra CEO Andre Vlok said the new product is another example of how the Company engages in collaborative and innovative partnerships with Australian healthcare professionals to deliver often intricate, fit-for-purpose pharmaceutical products.

"We received feedback from anaesthetists and surgeons about the value of pre-prepared sterile theatre packs, which are designed to make it more convenient to access medication directly from a sterile vial in the operating room. This prevents the risk of infections and improves the overall outcome for the patient," Mr. Vlok said.

"Our expanded multi-purpose plant at Lane Cove West has given us greater manufacturing capacity and capability and allowed us to commission a new line for the design and production of sterile theatre packs to meet the clinicians' specific needs for surgical procedures.

"The team at Phebra has always worked collaboratively with healthcare professionals in the specialist development, formulation and manufacture of intricate pharmaceutical products, and we're proud of our recent investment in an innovative sterile theatre pack manufacturing technology, the first of its kind developed in Australia by Australian scientists and engineers. We have optimised and improved conventional processes leading to sustainable domestic supply.

"It again reinforces Phebra's long-commitment to research and development (R&D) and local manufacturing, because as we experienced throughout the pandemic, it's critical that we, as a nation, have resilient supply chains to secure the delivery of critical medicines for Australian patients."

This year, Phebra is celebrating 30 years' of developing and manufacturing critical medicines, supplying institutions in Australia and overseas with over 65 products used to treat serious and life-threatening conditions.

Mr. Vlok said Phebra would be adding more medications to the Company's sterile theatre pack range in the future.

---

<sup>1</sup> Bupivacaine 0.5% with Adrenaline 1:200,000 Phebra Australian Product Information available at <https://www.phebra.com/wp-content/uploads/2023/02/Bupivacaine-0.5-with-Adrenaline-PI-V1.pdf>

## **About Phebra**

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

***At Phebra, we create critical medicines that save and improve lives.***

Phebra media contact: Richard Lenarduzzi +61 411 254 390